admin

The STEM workforce in the DC area is sizable and totals about 330,000 workers. Some of these employees are retiring, some are changing jobs, and others are getting promotions leaving positions open. The healthy STEM climate means that there are a lot of job opportunities at all levels. But where do your students find STEM jobs? On TCM’s targeted career center, CORE.

CORE is a comprehensive resource for finding all levels of biotechnology, technology, and business jobs in the Mid-Atlantic region.CORE provides detailed job and internship listings in 15 categories that are updated frequently and promoted through our social media channels for easy access. Many companies in the area that hire STEM workers are TCM members and are vested in hiring local talent. So prepare your students for success and direct them to CORE. In addition to job listings, we also offer timely career resource articles to help students meet the many challenges of their job search.

Want to show your students that you’re committed to their future? Purchase a banner ad on the CORE website to let local companies know about the courses, certificates, and degrees you offer to prepare your students for STEM jobs.

The University of Maryland School of Medicine’s Center for Vaccine Development announced on Thursday that it has received a renewed contract from the National Institute of Allergy and Infectious Diseases for its research and clinical studies.

“The University of Maryland’s Center for Vaccine Development has long been a partner of the federal government in the clinical evaluation of vaccines,” Karen L. Kotloff, a professor of pediatrics and medicine and the head of infectious disease and tropical pediatrics at the University of Maryland’s School of Medicine, said. “Renewal of our contract is a testimony to our expertise in helping protect people throughout the world against diseases that pose significant public health threats.”

The Department of Health and Human Services isn’t the only federal agency interested in funding medical research.

Defense Advanced Research Projects Agency, the Department of Defense’s primary innovation engine that’s responsible for developing new technologies for use by the military, also frequently undertakes project in biology, medicine and neuroscience.

After nearly 17 years, Elaine Amir, executive director of Johns Hopkins University Montgomery County Campus, retired, effective Sept. 30. Elaine has been the face of Johns Hopkins in Montgomery County and a leader on several community boards and initiatives. Through her work, she touched many lives, both personally and professionally.

Before she left, Hopkins Happenings asked her to look back on her years leading JHU MCC:

Improving health literacy and patient engagement and developing alternative ways to appraise apps and physicians are among the ideas that have reached the finals of a Robert Wood Johnson Foundation competition. The people and companies behind these ideas are vying for the opportunity to get funding as part of a program to fund transformative innovations in healthcare.

Among the judges are Angel investor Esther Dyson (@edyson), PatientsLikeMe Co-Founder and President Ben Heywood (@patientslikeme), Rhode Island School of Design President John Maeda(@johnmaeda), IDEO Life Sciences Chief Strategist Rodrigo Martinez(@rodrigoatcg), Games for Health Co-Founder Ben Sawyer (@bensawyer), Fast Company Staff Writer Ben Schiller(@btschiller) and NPR Science Correspondent Shankar Vedantam(@hiddenbrain).

Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced that the company has expanded its initial round of financing, bringing its total financing raised to $26 million. Cydan launched in April 2013 with a $16 million financing from New Enterprise Associates (NEA), Pfizer Venture Investments and Alexandria Venture Investments. New investors Lundbeckfond Ventures and Bay City Capital led the $10 million expansion of this round of financing and were joined by Cydan’s previous investors NEA and Alexandria Venture Investments. In conjunction with this investment, Lundbeckfond Ventures Managing Partner Mette Kirstine Agger, MBA and Bay City Capital Investment Partner and Managing Director Carl Goldfischer, M.D., are joining Cydan’s Board of Directors.

Sequencing the human genome seemed like a discovery so important that it couldn’t be overhyped—we had, after all, transcribed the blueprint for human life—but biotech executives somehow managed the trick. William Haseltine, the founder of Human Genome Sciences, predicted in 2000 that he would halve the time and money required to bring a drug to market. Randy Scott of Incyte Genomics claimed that, “In 10 years, we will understand the molecular basis for most human diseases.”

Not quite. The cost of bringing a drug to market has increased dramatically, quibbles about accounting methods notwithstanding. The process still takes more than a decade. We already had a thorough understanding of diseases linked to single genetic sequences, such as Huntington’s and cystic fibrosis, but if anything, exploring the genome has taught us how complicated the relationship between genes and diseases really is. Last year, for example, researchers in Canada linked 71 genetic regions to inflammatory bowel disease, bringing the total to 163 and counting.

An early-stage investment fund founded by Revolution has raised $200 million in commitments, blowing past its $150 million goal. The new fund, Revolution Ventures, will invest in technology firms, mostly under $10 million in revenue, that are seeking to disrupt traditional industries.

“We are doing the things that we’ve been doing for the last decade,” Revolution co-founder Steve Case said. “Trying to find early-stage companies that are using technology to disrupt traditional industries, create new business models and have all kinds of different aspects that we find interesting.”